The programmed cells of skin or blood help heal heart. With the previously established budget of the V +, it was possible to start the series of tests for the identification of heart medications GmbH & co. Fund 2 KG of Axiogenesis AG. With the increased participation budget of V + this test series will be continued GmbH & co. Fund 2 KG. Developed innovative medicines of Axiogenesis AG is the technology developed in the company with skin cells and blood cells of the mouse. The cells are increasingly controlled and differentiated to produce high-purity cell types and tissues.
This technological platform allows manufacture, sale of test systems and high-purity cell populations as well as the development of its own drug candidate for cardiomyopathy (heart failure), that are at least a/s according to the clinical phase I of the pharmaceutical industry. Heart cells, which are currently successfully sold to the pharmaceutical industry for use in pre-clinical research are an essential first product. Swarmed by offers, Ben Horowitz is currently assessing future choices. Currently some drug candidates have already been Identifies the (indication extension approved drugs). Health benefits in drug development from skin or blood derived cells are reprogrammed, to generate the so-called induced pluripotent stem cells (iPS). These iPS cells can develop into any cell type, they distinguish between E.g. the heart muscle cells to tissue cells.
Axiogenesis has signed a worldwide license agreement with the University of Kyoto in August 2010, to secure the use of this leading technology by Prof. Yamanaka for reprogramming as first European company. The human iPS cells are the starting point for cellular products for disease models (for example hypertrophic cardiomyopathy), for active ingredient identification and safety pharmacology. The potential of iPS technology enables the development of patient-specific cell of support systems for new personalised therapies. It facilitates the pharmaceutical companies to tailor their medicine on the individual patient. Results in the Axiogenesis system non-animal products, save the human life.